Pergolid

Key facts

Drug.Verifiedfields

changed

Drug.verifiedrevid

464199003

Drug.image

Pergolide structure.svg

Drug.image_class

skin-invert-image

Drug.width

165px

Drug.image2

PergolideMV.png

Drug.image_class2

bg-transparent

Drug.width2

225px

Drug.tradename

Permax, Prascend (veterinary), others

Drug.pregnancy_category

B

Drug.routes_of_administration

Oral

Drug.class

Dopamine receptor agonist; Antiparkinsonian agent

Drug.ATC_prefix

N04

Drug.ATC_suffix

BC02

Drug.legal_BR

C1

Drug.legal_CA

Rx-only

Drug.legal_US_comment

Veterinary use only, withdrawn for human use

Drug.protein_bound

90%

via Wikipedia infobox

Chemical data

Formula

C19H26N2S

Molecular weight

314.5 g/mol

IUPAC name

(6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline

SMILES

CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC

InChIKey

YEHCICAEULNIGD-MZMPZRCHSA-N

XLogP

4.2

Polar surface area

44.3 Ų

H-bond donors

1

H-bond acceptors

2

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Small molecule

First approval

1988

Admin. routes

oral

Indications

cocaine dependence, Parkinson disease, drug dependence

via ChEMBL · EBI

• Pergolide for levodopa-induced complications in Parkinson's disease.The Cochrane database of systematic reviews · 2000
• Pergolide-associated valvular heart disease.Comprehensive therapy · 2006
• Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.Veterinary journal (London, England : 1997) · 2020
• Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.Drugs · 1990
• Pergolide in the treatment of patients with early and advanced Parkinson's disease.Clinical neuropharmacology · 2002

via PubMed

Wikidata facts

Subclass of

ergot alkaloids

Mass

314.18167

Has use

medication

via Wikidata · CC0